Medivizor

Title of notification

Here comes the notification
X
 
icon
icon
coronary artery disease | Research | Treatment | 10 pages | source: BMJ Open | Added May 29, 2023

Comparing the effectiveness and safety between biodegradable and durable polymer drug-eluting stents in patients with acute coronary syndrome.

This study compared the effectiveness and safety between biodegradable polymer (BP) drug-eluting stents (DES) and durable polymer (DP) DESs in patients with acute coronary syndrome (ACS). The data showed that both stent types demonstrated excellent effectiveness and safety after 1 year. The authors suggested that BP-DES may be more favorable when treating patients with ACS as there was a slight increase in the risks of death or heart attacks in the DP-DES group after 2 years.

icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Lancet (London, England) | Added May 27, 2023

Benefits of combination treatment for diabetic peripheral neuropathic pain.

This study evaluated the effectiveness and safety of combinations of anti-depressive medication for the treatment of diabetic peripheral neuropathic pain (DPNP) in patients with diabetes. The study showed that combination treatment improved pain in these patients and was well tolerated. 

icon
icon
parkinson's disease | Research | Treatment | 10 pages | source: Movement disorders: official journal of the Movement Disorder Society | Added May 26, 2023

Evaluating the effects of split-belt treadmill versus tied-belt treadmill training on gait adaptation in patients with Parkinson’s disease.

This study evaluated the effects of split-belt treadmill (SBT) versus tied-belt treadmill (TBT) training on gait adaptation in patients with Parkinson’s disease (PD). The data showed that SBT training significantly improved gait adaptation compared to TBT in these patients. 

icon
icon
coronary artery disease | Research | Treatment | 10 pages | source: Advances in therapy | Added May 26, 2023

Evaluating the effectiveness and safety of ivabradine in combination with beta-blockers in patients with stable angina.

This study evaluated the effectiveness and safety of ivabradine (Procoralan) in combination with beta-blockers in patients with stable angina. The data showed that the combination of ivabradine plus beta-blocker therapy effectively reduced heart rate, angina symptoms, and the use of short-acting nitrates from the first month of treatment and was safe with manageable side effects in these patients.

icon
icon
hodgkin's lymphoma | Research | Treatment | 10 pages | source: Frontiers in oncology | Added May 25, 2023

Evaluating the effectiveness and safety of penpulimab in patients with relapsed or refractory classical Hodgkin lymphoma.

This study evaluated the effectiveness and safety of penpulimab (AK105) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that penpulimab was effective and safe with manageable side effects in these patients.

icon
icon
diabetes mellitus | Research | Treatment | 10 pages | source: Diabetes Research and Clinical Practice | Added May 25, 2023

Do some anti-diabetic medications affect the risk of fractures in patients with type 2 diabetes?

This analysis investigated the relationship between anti-diabetic medications and the risk of fractures in patients with type 2 diabetes (T2D). The data showed that glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sulfonylurea (SU) provided better protection against fractures compared to thiazolidinedione (TZD) or dipeptidyl peptidase-4 inhibitors (DPP-4is) while sodium-glucose cotransporter-2 inhibitors (SGLT-2i) increased the risk of fractures compared to GLP1-RAs.

icon
icon
erectile dysfunction | Research | Treatment | 10 pages | source: Investigative and clinical urology | Added May 24, 2023

Comparing the effectiveness and safety of intralesional verapamil and collagenase Clostridium histolyticum injections in men with Peyronie’s disease.

This study compared the effectiveness and safety of intralesional verapamil (Calan; ILV) and collagenase Clostridium histolyticum (Xiaflex; CCH) injections in men with Peyronie’s disease (PD). The data showed that CCH therapy was more effective than ILV, with a higher high level of patient satisfaction rate in the short term and with manageable side effects.

icon
icon
coronary artery disease | Research | Treatment | 10 pages | source: Circulation | Added May 24, 2023

Evaluating the effect of patient-reported physical and mental health status before PCI/CABG on their long-term outcomes

This study evaluated the effect of patient-reported physical and mental health status before revascularization procedures such as percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) on their long-term outcomes in patients with coronary artery disease (CAD). The data showed that patient-reported physical and mental health status before the procedures was strongly associated with long-term mortality in these patients. Patients with the best physical and mental health had better 10-year survival with CABG compared with PCI.

icon
icon
diabetes mellitus | Research | Lifestyle | 10 pages | source: Diabetes Research and Clinical Practice | Added May 23, 2023

How can counselling affect pancreatic beta-cell function in patients with type 2 diabetes?

This study analyzed the long-term effect of behavioral counseling on increasing daily physical activity (PA) and reducing sedentary (SED) time on changes in beta-cell (β-cell) function and glucose control in patients with type 2 diabetes (T2D). The authors concluded that increasing moderate-to-vigorous-intensity physical activity (MVPA) and reducing SED time can effectively preserve the β-cell function of the pancreas and improve glucose control in these patients.

icon
icon
colorectal cancer | Research | Treatment | 10 pages | source: The Lancet. Oncology | Added May 23, 2023

Evaluating the safety and effectiveness of FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of metastatic colorectal cancer

This study evaluated the effectiveness and safety of FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab (Avastin) with or without atezolizumab (Tecentriq) on the outcomes of patients with metastatic (m) colorectal cancer (CRC). The study showed that adding atezolizumab to FOLFOXIRI plus bevacizumab regimen was safe and improved survival outcomes in these patients.

View

Conditions

Category

  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon

Was this helpful?